国产精品毛片VA无遮挡,精品国产日本在线观看,久久久久久久久国产精品,日本欧美一区人妻中文字幕

掃碼關注公眾號           掃碼咨詢技術支持           掃碼咨詢技術服務
  
客服熱線:400-901-9800  客服QQ:4009019800  技術答疑  技術支持  質量反饋  人才招聘  關于我們  聯(lián)系我們
成人午夜福利视频网址,婷婷色在线精品国自产拍,大伊香蕉在线观看国产
首頁 > 產(chǎn)品中心 > 標記一抗 > 產(chǎn)品信息
Rabbit Anti-CRTAM/PE-Cy5.5 Conjugated antibody (bs-4957R-PE-Cy5.5)
訂購熱線:400-901-9800
訂購郵箱:sales@m.hebaili.cn
訂購QQ:  400-901-9800
技術支持:techsupport@m.hebaili.cn
說 明 書: 100ul  
100ul/2980.00元
大包裝/詢價
產(chǎn)品編號 bs-4957R-PE-Cy5.5
英文名稱1 Rabbit Anti-CRTAM/PE-Cy5.5 Conjugated antibody
中文名稱 PE-Cy5.5標記的T細胞調控相關蛋白抗體
別    名 CD355; Class I MHC restricted T cell associated molecule; Class-I MHC-restricted T-cell-associated molecule; CRTAM; CRTAM_HUMAN; Cytotoxic and regulatory T cell molecule; Cytotoxic and regulatory T-cell molecule.  
規(guī)格價格 100ul/2980元 購買        大包裝/詢價
說 明 書 100ul  
研究領域 細胞生物  細胞類型標志物  自然殺傷細胞  淋巴細胞  t-淋巴細胞  
抗體來源 Rabbit
克隆類型 Polyclonal
交叉反應 (predicted: Human, Mouse, Rat, Pig, Rabbit, )
產(chǎn)品應用 Flow-Cyt=1:50-200 ICC=1:50-200 IF=1:50-200 
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量 42kDa
性    狀 Lyophilized or Liquid
濃    度 1mg/ml
免 疫 原 KLH conjugated synthetic peptide derived from human CRTAM
亞    型 IgG
純化方法 affinity purified by Protein A
儲 存 液 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
保存條件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
產(chǎn)品介紹 background:
CRTAM, (class-I MHC-restricted T-cell associated molecule), is an immunoglobulin-superfamily transmembrane protein and a new member of the nectin-like (Necls) family. In the immune system, CRTAM expression has been shown to be restricted to activated class-I MHC-restricted T cells, including NKT and CD8 T cells. CRTAM interacts with CADM1 and promotes natural killer (NK) cell cytotoxicity and interferon-gamma (IFN-gamma) secretion by CD8+ cells in vitro, as well as NK cell-mediated rejection of tumors expressing CADM3 in vivo. Nectin-like (Necl) molecule 2, has been identified as a ligand of CRTAM. Necl2/CRTAM molecular pair could regulate a large panel of cell/cell interactions both within and outside of the immune system.

Function:
Interaction with CADM1 promotes natural killer (NK) cell cytotoxicity and interferon-gamma (IFN-gamma) secretion by CD8+ cells in vitro as well as NK cell-mediated rejection of tumors expressing CADM3 in vivo.

Subunit:
Interacts with CADM1.

Subcellular Location:
Membrane; Single-pass type I membrane protein (Potential).

Tissue Specificity:
In the immune system, expression is restricted to activated class-I MHC-restricted cells, including NKT and CD8 cells. Strongly expressed in spleen, thymus, small intestine, peripheral blood leukocyte, and in Purkinje neurons in cerebellum. Expressed at much lower levels in testis, ovary, colon, lung and lymphoid tissues.

Similarity:
Belongs to the nectin family.
Contains 1 Ig-like C2-type (immunoglobulin-like) domain.
Contains 1 Ig-like V-type (immunoglobulin-like) domain.

Database links:

Entrez Gene: 56253 Human

GenBank: BC070266.1 Human

Omim: 612597 Human

SwissProt: O95727 Human

Unigene: 159523 Human



Important Note:
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

CRTAM蛋白與調節(jié)細胞極性有關。細胞極性(cell polarity)的調控對于控制細胞的形態(tài)發(fā)生非常關鍵,并且這一過程在很多生物學功能中發(fā)揮著重要的作用,包括細胞分裂、分化、遷移等基礎過程以及器官發(fā)生中的復雜行為等。細胞蛋白的空間結構排列是細胞極性形成的基礎??乖蔬f細胞(antigen-presenting cell,APC)誘導T細胞的激活,而這會導致免疫突觸(immunological synapse,IS)的形成、T細胞受體(TCR)接觸信號銜接平臺的組裝、細胞支架的重組以及第二信使的產(chǎn)生等。
版權所有 2004-2026 www.m.hebaili.cn 北京博奧森生物技術有限公司
通過國際質量管理體系ISO 9001:2015 GB/T 19001-2016    證書編號: 00124Q34771R2M/1100
通過國際醫(yī)療器械-質量管理體系ISO 13485:2016 GB/T 42061-2022    證書編號: CQC24QY10047R0M/1100
京ICP備05066980號-1         京公網(wǎng)安備110107000727號
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |